Abstract: The present invention is in the field of biomedicine pharmaceutical chemistry. Specifically, it refers to the use of yessotoxin, its derivatives and analogues, for the preparation of a medicinal drug for the prevention and/or treatment of neurodegenerative diseases related to abnormal levels of Tau and ?-amyloid proteins such as, for example, Alzheimer's disease.

Abstract: The present invention relates to the use of a compound with the following chemical structure: for the preparation of a medicament, preferably designed for the prevention or treatment of pathological processes related to the tau and ?-amyloid proteins. Preferably, the compound used is gambierol.

Abstract: The present invention refers to the use of a compound with the chemical structure for the preparation of a medicinal drug, preferably for the prevention or the treatment of pathological processes related to the tau and ?-amyloid proteins. The compound preferably used is gymnodimine.

Abstract: The present invention relates to a quantitative method for detecting yessotoxins in fishery products based on the activation the toxin produces on cellular phosphodiesterases and the therapeutic use of this activation. The cellular target of yessotoxin (YTX) and its analogs is the activation of phosphodiesterases (PDEs). The PDEs-YTX bond produces a measurable signal. The bond can be quantified by means of an affinity biosensor or by fluorescence. The biosensor detects biomolecular interactions and allows determining the presence of YTX due to its interaction with PDEs. The variations in the degradation rate of the fluorescent derivative anthraniloyl-cAMP are determined by means of plate fluorescence. The rate at which the PDEs degrade this molecule increases in the presence of YTX. YTX inhibits immunological activation of mastocytes in rats and induces a cytotoxic effect in human hepatocarcinoma cells, which implies two therapeutic uses of YTXs as an antiallergic and antitumor compound.